GlobeNewsWire
29 Sept 2026, 12:45 UTC · 7w ago
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Impact · against what's priced in
Vivos Therapeutics is providing a concrete roadmap to profitability via a combination of $3.6 million in overhead cuts and several new revenue streams. The combined impact of these initiatives significantly increases the probability of the company achieving cash flow positivity by early 2027.
- VVOS+0.70
No priced-in read yet





